You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Eribulin Mesylate

Showing 1 - 25 of 615
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

Recruiting
  • Triple Negative Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022

HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Eribulin mesylate injection、Pertuzumab、Trastuzumab
  • Guanzhou, Guangdong, China
    LI YuDong
Jul 13, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Terminated
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Bintrafusp Alfa
  • Eribulin Mesylate
  • Houston, Texas
  • +1 more
Oct 27, 2022

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (MEN1611, Eribulin)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • (no location specified)
Apr 12, 2023

Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)

Not yet recruiting
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • (no location specified)
Jan 31, 2023

Breast Cancer Trial in Boston (Eribulin Mesylate, Pembrolizumab)

Active, not recruiting
Has Results
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
Apr 18, 2022

Breast Cancer Trial in Tampa (Eribulin, Carboplatin)

Completed
  • Breast Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Oct 28, 2022

Metastatic Malignant Tumor in the Adult Brain, Primary Brain Tumor Trial in Duarte (procedure, drug, other)

Active, not recruiting
  • Metastatic Malignant Neoplasm in the Adult Brain
  • Primary Brain Tumor
  • Therapeutic Conventional Surgery
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Mar 16, 2022

Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative Trial in Duarte, Rancho Cucamonga, South Pasadena

Completed
Has Results
  • Estrogen Receptor Negative
  • +4 more
  • Duarte, California
  • +2 more
Jun 6, 2022

Liposarcoma, Malignant Abdominal Tumor, Malignant Retroperitoneal Tumor Trial in Portland (drug, radiation, other, procedure)

Recruiting
  • Liposarcoma
  • +5 more
  • Eribulin Mesylate
  • +5 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Oct 17, 2022

Metastatic Breast Cancer Trial in Changsha (Eribulin Mesylate, Anlotinib)

Recruiting
  • Metastatic Breast Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
May 4, 2022

Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma Trial in Houston

Recruiting
  • Breast Inflammatory Carcinoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2022

Breast Tumor Trial in United States (Eribulin Mesylate, Pembrolizumab)

Completed
Has Results
  • Breast Neoplasm
  • Duarte, California
  • +21 more
Apr 6, 2022

Triple-Negative Breast Cancer Trial in Shanghai (VEGFR, nab-paclitaxel, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin)

Recruiting
  • Triple-Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Mar 28, 2023

Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Bronx (Rebastinib,

Terminated
  • Breast Cancer
  • +4 more
  • Bronx, New York
    Montefiore Medical Center
Mar 23, 2022

Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral

Recruiting
  • Locally Advanced Renal Pelvis Urothelial Carcinoma
  • +20 more
  • Duarte, California
  • +16 more
Aug 10, 2022

Triple-Negative Breast Cancer Trial in Shanghai (Famitinib, Camrelizumab, nab-Palitaxel/Capecitabine/Eribulin

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 27, 2023

Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,

Active, not recruiting
Has Results
  • Inflammatory Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Boston, Massachusetts
  • +1 more
Nov 28, 2022

Bladder Cancer Trial in Worldwide (Gemcitabine, E7389, Cisplatin)

Terminated
Has Results
  • Bladder Cancer
  • Birmingham, Alabama
  • +41 more
Feb 3, 2022

HER2-negative Breast Cancer Trial in Nanjing (Eribulin Mesylate, Anlotinib HCl)

Recruiting
  • HER2-negative Breast Cancer
  • Eribulin Mesylate
  • Anlotinib hydrochloride
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Hospital
May 19, 2021

Metastatic Breast Cancer Trial in Italy (Eribulin Mesylate, Capecitabine)

Active, not recruiting
  • Metastatic Breast Cancer
  • Brescia, Italy
  • +24 more
Apr 18, 2023

Breast Cancer Trial in Guangzhou, Shanghai (Camrelizumab, Apatinib, Eribulin)

Active, not recruiting
  • Breast Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Jul 24, 2021

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Suspended
  • Anatomic Stage III Breast Cancer AJCC v8
  • +12 more
  • Copanlisib Hydrochloride
  • Eribulin Mesylate
  • Gainesville, Florida
  • +10 more
Nov 16, 2022

Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma Trial in United States (Eribulin

Completed
Has Results
  • Relapsed/Refractory Rhabdomyosarcoma
  • +2 more
  • Eribulin mesylate
  • Birmingham, Alabama
  • +40 more
Mar 18, 2022

Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma Trial in United States (Eribulin Mesylate, Laboratory

Suspended
  • Breast Adenocarcinoma
  • +4 more
  • Eribulin Mesylate
  • +3 more
  • Scottsdale, Arizona
  • +38 more
May 25, 2022